USES SKYRIZI is a prescription medicine used to treat adults with: moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV …

DOSING & MONITORING GUIDE INDICATIONS1 Crohn’s Disease: SKYRIZI is indicated for the treatment of moderately to severely active Crohn’s disease in adults. Ulcerative Colitis: SKYRIZI is …

Jul 14, 2025 · In ulcerative colitis treatment options, the addition of SKYRIZI has helped AbbVie strengthen its IBD portfolio. SKYRIZI and RINVOQ are performing exceptionally well and are …

Jun 18, 2024 · The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) …

Jul 23, 2024 · As a treatment for ulcerative colitis, Skyrizi works by fighting the inflammation that can lead to symptoms of the disease.

Jun 2, 2025 · As gastroenterologists navigate the unmet needs of refractory ulcerative colitis, the FDA approval of risankizumab for ulcerative colitis marks a watershed moment, introducing the first IL-23 …

SKYRIZI® is also indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or were intolerant to …

Nov 28, 2025 · Potential Positives SKYRIZI® received positive reimbursement recommendations from Canada’s Drug Agency, enhancing access to treatment for ulcerative colitis for many patients. …

Nov 28, 2025 · SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel …

Discover your goals for ulcerative colitis treatment with SKYRIZI® (risankizumab-rzaa). See full Safety and Prescribing Information.